SARS-CoV-2加强疫苗接种在人类免疫缺陷病毒感染者中诱导强效免疫应答
单臂开放标签研究纳入CD4计数>350细胞/µL且病毒学抑制的HIV感染者,两剂ChAdOx1 nCoV-19后12个月接种第三剂异源疫苗。第三剂后抗棘突IgG、ACE-2抑制及ELISA结果较第182天显著升高(P<.0001),CD4+和CD8+ T细胞应答增强,对Alpha、Beta、Gamma、Delta变异株应答提升,对Omicron提升幅度较小。
要点
- HIV感染者完成两剂ChAdOx1后12个月接种第三剂异源mRNA疫苗,体液免疫显著增强。
- 第三剂后抗棘突IgG、ACE-2抑制及ELISA较第182天显著升高(P<.0001)。
- 对Alpha、Beta、Gamma、Delta变异株应答提升,对Omicron提升幅度较小。
核心结论
- 在接受第三剂疫苗的HIV感染者中,B细胞和T细胞免疫显著增加,包括对已知关注变异株的免疫应答。
研究设计与样本
- 单臂开放标签研究,纳入接受抗逆转录病毒治疗、病毒学抑制且CD4计数>350细胞/µL的HIV成人感染者。
- 54名参与者接种两剂ChAdOx1 nCoV-19,其中43人在首剂后1年接种第三剂异源疫苗(42人BNT162b2,1人mRNA-1273)。
主要发现
- 第三剂后总抗SARS-CoV-2棘突IgG滴度(MSD)、ACE-2抑制和IgG ELISA结果均显著高于第182天滴度(P<.0001)。
- 第三剂后针对SARS-CoV-2 S1和S2肽池的AIM CD4+ T细胞应答较首剂后6个月显著增加。
- 加强后针对SARS-CoV-2 S1和S2的增殖性CD4+和CD8+ T细胞应答显著增加。
- 对Alpha、Beta、Gamma和Delta变异株的应答得到增强,对Omicron的增强幅度较小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. METHODS: Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. FINDINGS: In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. CONCLUSIONS: In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs).
引用
- Fidler S, Fox J, Tipoe T, et al. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. Clin Infect Dis. 2023. PMID: 36196614. doi:10.1093/cid/ciac796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。